703 related articles for article (PubMed ID: 26668346)
1. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Hong TS; Wo JY; Yeap BY; Ben-Josef E; McDonnell EI; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Goyal L; Murphy JE; Javle MM; Wolfgang JA; Drapek LC; Arellano RS; Mamon HJ; Mullen JT; Yoon SS; Tanabe KK; Ferrone CR; Ryan DP; DeLaney TF; Crane CH; Zhu AX
J Clin Oncol; 2016 Feb; 34(5):460-8. PubMed ID: 26668346
[TBL] [Abstract][Full Text] [Related]
2. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors.
Hong TS; DeLaney TF; Mamon HJ; Willett CG; Yeap BY; Niemierko A; Wolfgang JA; Lu HM; Adams J; Weyman EA; Arellano RS; Blaszkowsky LS; Allen JN; Tanabe KK; Ryan DP; Zhu AX
Pract Radiat Oncol; 2014; 4(5):316-322. PubMed ID: 25194100
[TBL] [Abstract][Full Text] [Related]
3. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
Ohkawa A; Mizumoto M; Ishikawa H; Abei M; Fukuda K; Hashimoto T; Sakae T; Tsuboi K; Okumura T; Sakurai H
J Gastroenterol Hepatol; 2015 May; 30(5):957-63. PubMed ID: 25376272
[TBL] [Abstract][Full Text] [Related]
4. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
[TBL] [Abstract][Full Text] [Related]
5. Image-guided radiation therapy for liver tumors: gastrointestinal histology matters.
Katsoulakis E; Riaz N; Cannon DM; Goodman K; Spratt DE; Lovelock M; Yamada Y
Am J Clin Oncol; 2014 Dec; 37(6):561-7. PubMed ID: 23466584
[TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
[TBL] [Abstract][Full Text] [Related]
7. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population-based analysis.
Spolverato G; Bagante F; Tsilimigras D; Ejaz A; Cloyd J; Pawlik TM
J Surg Oncol; 2019 Mar; 119(3):278-287. PubMed ID: 30554420
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
Parzen JS; Hartsell W; Chang J; Apisarnthanarax S; Molitoris J; Durci M; Tsai H; Urbanic J; Ashman J; Vargas C; Stevens C; Kabolizadeh P
Radiat Oncol; 2020 Nov; 15(1):255. PubMed ID: 33148296
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.
Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A
J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849
[TBL] [Abstract][Full Text] [Related]
10. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
11. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
12. Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial.
Niska JR; Keane FK; Wolfgang JA; Hahn PF; Wo JY; Zhu AX; Hong TS
Pract Radiat Oncol; 2016; 6(1):e9-16. PubMed ID: 26598907
[TBL] [Abstract][Full Text] [Related]
13. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
15. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis.
Hata M; Tokuuye K; Sugahara S; Fukumitsu N; Hashimoto T; Ohnishi K; Nemoto K; Ohara K; Matsuzaki Y; Akine Y
Strahlenther Onkol; 2006 Dec; 182(12):713-20. PubMed ID: 17149578
[TBL] [Abstract][Full Text] [Related]
16. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.
Bergquist JR; Groeschl RT; Ivanics T; Shubert CR; Habermann EB; Kendrick ML; Farnell MB; Nagorney DM; Truty MJ; Smoot RL
HPB (Oxford); 2016 Nov; 18(11):886-892. PubMed ID: 27546172
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Smart AC; Goyal L; Horick N; Petkovska N; Zhu AX; Ferrone CR; Tanabe KK; Allen JN; Drapek LC; Qadan M; Murphy JE; Eyler CE; Ryan DP; Hong TS; Wo JY
Ann Surg Oncol; 2020 Apr; 27(4):1122-1129. PubMed ID: 31873931
[TBL] [Abstract][Full Text] [Related]
18. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.
Hyder O; Marsh JW; Salem R; Petre EN; Kalva S; Liapi E; Cosgrove D; Neal D; Kamel I; Zhu AX; Sofocleous CT; Geschwind JF; Pawlik TM
Ann Surg Oncol; 2013 Nov; 20(12):3779-86. PubMed ID: 23846786
[TBL] [Abstract][Full Text] [Related]
19. Impact of pretreatment cholinesterase level on survival of inoperable intrahepatic or hepatic-hilar carcinomas treated with three-dimensional conformal radiotherapy.
Hamamoto Y; Niino K; Ishiyama H; Hosoya T
Radiat Med; 2004; 22(5):316-23. PubMed ID: 15553012
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy.
Shimizu S; Okumura T; Oshiro Y; Fukumitsu N; Fukuda K; Ishige K; Hasegawa N; Numajiri H; Murofushi K; Ohnishi K; Mizumoto M; Nonaka T; Ishikawa H; Sakurai H
Radiat Oncol; 2019 Dec; 14(1):241. PubMed ID: 31881895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
